Syros Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Syros Pharmaceuticals's estimated annual revenue is currently $21.4M per year.
- Syros Pharmaceuticals received $40.0M in venture funding in February 2018.
- Syros Pharmaceuticals's estimated revenue per employee is $213,900
- Syros Pharmaceuticals's total funding is $525.5M.
- Syros Pharmaceuticals's current valuation is $162.3M. (January 2022)
Employee Data
- Syros Pharmaceuticals has 100 Employees.
- Syros Pharmaceuticals grew their employee count by -27% last year.
Syros Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Legal & Compliance Officer | Reveal Email/Phone |
3 | SVP | Reveal Email/Phone |
4 | VP, Clinical Operations | Reveal Email/Phone |
5 | VP Human Resources | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | VP, Business Development | Reveal Email/Phone |
8 | Head Information Technology | Reveal Email/Phone |
9 | VP, Head Clinical Development | Reveal Email/Phone |
10 | VP, Global Product Leadership | Reveal Email/Phone |
Syros Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Syros Pharmaceuticals?
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros lead drug candidates are SY-1425, a selective RAR agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
$525.5M
Total Funding
100
Number of Employees
$21.4M
Revenue (est)
-27%
Employee Growth %
$162.3M
Valuation
N/A
Accelerator
Syros Pharmaceuticals News
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and...
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and...
By Stephen Nakrosis. Shares of Syros Pharmaceuticals Inc. were up on the Nasdaq on Friday, after the company said preclinical data from its...
Shares of Syros were down 32.3 percent on the Nasdaq following the news. The company has consequently decided to shift its focus from SY-1365 to another drug, the oral CDK7 inhibitor SY-5609, which it said inhibits CDK7 more selectively and potently than SY-1365 and in preclinical testing has s ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.5M | 100 | -21% | $470.6M |
#2 | $25.1M | 100 | 20% | N/A |
#3 | $16M | 100 | 6% | N/A |
#4 | $22M | 101 | 1% | $478.3M |
#5 | $15.7M | 101 | -16% | $380.7M |
Syros Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-04-12 | $30.0M | A | ARCH Venture Partners, Flagship Ventures | Article |
| 2014-10-28 | $53.0M | B | Article | |
| 2016-01-13 | $40.0M | Undisclosed | Deerfield Management Company | Article |
| 2017-04-24 | $35.0M | Undisclosed | Samsara BioCapital | Article |
| 2018-02-01 | $40.0M | Undisclosed | JMP Securities LLC | Article |